国际呼吸杂志
國際呼吸雜誌
국제호흡잡지
INTERNATIONAL JOURNAL OF RESPIRATION
2014年
7期
504-507
,共4页
慢性阻塞性肺疾病%沙美特罗氟替卡松%丙酸氟替卡松气雾剂%荼碱缓释片%肺功能
慢性阻塞性肺疾病%沙美特囉氟替卡鬆%丙痠氟替卡鬆氣霧劑%荼堿緩釋片%肺功能
만성조새성폐질병%사미특라불체잡송%병산불체잡송기무제%도감완석편%폐공능
Chronic obstructive pulmonary disease%Salmeterol fluticasone%Fluticasone aerosol%Theophylline retard tablet%Pulmonary function
目的：研究 COPD 稳定期的不同治疗方案。方法将90例 COPD 患者随机分为3组：舒利迭组(吸入沙美特罗氟替卡松50/250μg 每天2次)、联合用药组(口服茶碱缓释片0.1 g 每天2次+吸入丙酸氟替卡松125μg 每天2次)及对照组(按需使用硫酸沙丁胺醇气雾剂),随访1年,观察1年后的肺功能(FEV1、FVC、FEV1% pred、FEV1/FVC 和 FEF25-75%),6分钟步行距离(6 minutes walking distance,6MWD)和1年中急性加重的次数。结果治疗后舒利迭组和联合用药组的 FEV1、FVC、FEV1%pred、FEV1/FVC、FEF25-75%和6MWD 分别与对照组及治疗前比较均有改善(P 值均<0.05)；治疗后舒利迭组比联合用药组 FVC 和 FEF25-75%改善更明显(分别为2.41±0.61和2.11±0.47,44.9±10.1和35.4±8.8,P 值均<0.05)。结论舒利迭(50/250μg)、联合用药(口服茶碱缓释片+丙酸氟替卡松气雾剂)对稳定期 COPD 患者疗效肯定,前者对 FVC 和 FEF25-75%的改善较后者强。
目的：研究 COPD 穩定期的不同治療方案。方法將90例 COPD 患者隨機分為3組：舒利迭組(吸入沙美特囉氟替卡鬆50/250μg 每天2次)、聯閤用藥組(口服茶堿緩釋片0.1 g 每天2次+吸入丙痠氟替卡鬆125μg 每天2次)及對照組(按需使用硫痠沙丁胺醇氣霧劑),隨訪1年,觀察1年後的肺功能(FEV1、FVC、FEV1% pred、FEV1/FVC 和 FEF25-75%),6分鐘步行距離(6 minutes walking distance,6MWD)和1年中急性加重的次數。結果治療後舒利迭組和聯閤用藥組的 FEV1、FVC、FEV1%pred、FEV1/FVC、FEF25-75%和6MWD 分彆與對照組及治療前比較均有改善(P 值均<0.05)；治療後舒利迭組比聯閤用藥組 FVC 和 FEF25-75%改善更明顯(分彆為2.41±0.61和2.11±0.47,44.9±10.1和35.4±8.8,P 值均<0.05)。結論舒利迭(50/250μg)、聯閤用藥(口服茶堿緩釋片+丙痠氟替卡鬆氣霧劑)對穩定期 COPD 患者療效肯定,前者對 FVC 和 FEF25-75%的改善較後者彊。
목적：연구 COPD 은정기적불동치료방안。방법장90례 COPD 환자수궤분위3조：서리질조(흡입사미특라불체잡송50/250μg 매천2차)、연합용약조(구복다감완석편0.1 g 매천2차+흡입병산불체잡송125μg 매천2차)급대조조(안수사용류산사정알순기무제),수방1년,관찰1년후적폐공능(FEV1、FVC、FEV1% pred、FEV1/FVC 화 FEF25-75%),6분종보행거리(6 minutes walking distance,6MWD)화1년중급성가중적차수。결과치료후서리질조화연합용약조적 FEV1、FVC、FEV1%pred、FEV1/FVC、FEF25-75%화6MWD 분별여대조조급치료전비교균유개선(P 치균<0.05)；치료후서리질조비연합용약조 FVC 화 FEF25-75%개선경명현(분별위2.41±0.61화2.11±0.47,44.9±10.1화35.4±8.8,P 치균<0.05)。결론서리질(50/250μg)、연합용약(구복다감완석편+병산불체잡송기무제)대은정기 COPD 환자료효긍정,전자대 FVC 화 FEF25-75%적개선교후자강。
Objective To research different treatment for patients with stable chronic obstructive pulmonary disease (COPD).Methods The 90 patients were divided into three groups:shulidie group (inhaled salmeterol (50 μg)fluticasone (250 μg)twice daily,drug combination group [taked theophylline retard tablets (0.1 g)by mouth and inhaled fluticasone (125 μg)twice daily]and control group(inhaled salbutamol in need).Pulmonary function (FEV1 ,FVC,FEV1 %predicted,FEV1/FVC and FEF25-75%), 6 minute walking distance and the exacerbations were observed during the 1-year treatment period.Results Both shulidie and drug combination groups resulted in improvements in pulmonary function (FEV1 , FVC,FEV1 %predicted,FEV1/FVC and FEF25-75%)and 6 minute walking distance at the end of the 1-year treatment period when compared with control group or baseline (all P < 0.05 ).Shulidie group improved the FEF25-75% and FVC value to a greater extent than control group (2.41±0.61 and 2.1 1± 0.47,44.9±10.1 and 35.4 ±8.8,respectively,both P <0.05 ).Conclusions The shulidie (50/250 μg) and combination drug (theophylline retard tablet and fluticasone aerosol)have effect for patients with stable COPD.The former has stronger effect to improve FVC and FEF25-75% than latter.
